Stock Scorecard
Stock Summary for Gilead Sciences Inc (GILD)
Total Score
12 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for GILD
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for GILD
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for GILD
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for GILD
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Financial Details for GILD
Company Overview |
|
|---|---|
| Company Name | Gilead Sciences Inc |
| Country | USA |
| Description | Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 9/30/2022 |
| Next Earnings Date | 1/30/2023 |
Stock Price History |
|
| Last Day Price | 86.26 |
| Last Day Volume | 0 |
| Average Daily Volume | 8,764,185 |
| 52-Week High | 86.41 |
| 52-Week Low | 55.27 |
| Last Price to 52 Week Low | 56.07 % |
Valuation Measures |
|
| Trailing PE | 32.36 |
| Industry PE | 221.48 |
| Sector PE | 93.04 |
| 5-Year Average PE | 8.99 |
| Free Cash Flow Ratio | 112.03 |
| Industry Free Cash Flow Ratio | 9.58 |
| Sector Free Cash Flow Ratio | 37.55 |
| Book Value Per Share Most Recent Quarter | 16.81 |
| Price to Book Ratio | 4.98 |
| Industry Price to Book Ratio | 11.33 |
| Sector Price to Book Ratio | 15.35 |
| Price to Sales Ratio Twelve Trailing Months | 3.95 |
| Industry Price to Sales Ratio Twelve Trailing Months | 43.53 |
| Sector Price to Sales Ratio Twelve Trailing Months | 25.22 |
Share Statistics |
|
| Total Shares Outstanding | 1,254,240,000 |
| Market Capitalization | 108,190,742,400 |
| Institutional Ownership | 0.00 % |
Dividends |
|
| Ex-Dividend Date | 12/14/2022 |
| Last Dividend Amount | 0.73 |
| Current Dividend Amount | 0.73 |
| Dividend Aristocrat? | False |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00 % |
| Trailing Annual Dividend Rate | 2.90 |
| Trailing Annual Dividend Yield | 3.43 % |
| 5-Year Average Dividend Yield | 0.00 % |
| 5-Year Dividend Payments Count | 21 |
| Dividend Payout Ratio | 0.00 % |
Income Statement |
|
| Quarterly Earnings Growth YOY | -30.70 % |
| Annual Earnings Growth | 4,960.98 % |
| Reported EPS Past Year | 5.60 |
| Reported EPS Prior Year | 7.29 |
| Net Income Twelve Trailing Months | 3,334,000,000 |
| Net Income Past Year | 6,225,000,000 |
| Net Income Prior Year | 123,000,000 |
| Quarterly Revenue Growth YOY | -5.10 % |
| 5-Year Revenue Growth | 0.21 % |
Balance Sheet |
|
| Total Cash Per Share | 0.77 |
| Total Cash Most Recent Quarter | 961,000,000 |
| Total Cash Past Year | 6,520,000,000 |
| Total Cash Prior Year | 7,408,000,000 |
| Net Cash Position Most Recent Quarter | -24,262,000,000 |
| Net Cash Position Past Year | -20,175,000,000 |
| Long Term Debt Past Year | 26,695,000,000 |
| Long Term Debt Prior Year | 31,402,000,000 |
| Total Debt Most Recent Quarter | 25,223,000,000 |
| Equity to Debt Ratio Past Year | 0.44 |
| Equity to Debt Ratio Most Recent Quarter | 0.46 |
| Current Ratio Most Recent Quarter | 1.30 |
| Total Stockholder Equity Past Year | 21,069,000,000 |
| Total Stockholder Equity Prior Year | 18,202,000,000 |
| Total Stockholder Equity Most Recent Quarter | 21,081,000,000 |
Options |
|
| Put/Call Ratio | 1.70 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| MACD | 3.95 |
| MACD Signal | 4.01 |
| 20-Day Bollinger Lower Band | 59.27 |
| 20-Day Bollinger Middle Band | 61.71 |
| 20-Day Bollinger Upper Band | 64.15 |
| Beta | 0.44 |
| RSI | 79.24 |
| 50-Day SMA | 63.95 |
| 200-Day SMA | 61.72 |
System |
|
| Modified | 11/26/2022 11:17:06 AM |